Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for rare hunger disorder: drug shows promise in Long-Term trial

NCT ID NCT07197034

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to improve quality of life by controlling the constant urge to eat.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

19 people

The number who actually took part.

Started

Jul 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

13 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who have completed treatment on Aardvark Therapeutics clinical study AVK-101-301 Exclusion Criteria: * Any complications that makes participation unsafe in the Investigator's opinion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperphagia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ajou University Hospital

    Suwon, 16499, South Korea

  • Alberta Children's Hospital Research Institute

    Calgary, Alberta, T3B 6A8, Canada

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois, 60611-2991, United States

  • Centre Hospitalier Universitaire Sainte-Justine

    Montreal, Quebec, H3T 1C5, Canada

  • Children's Hospital Colorado

    Denver, Colorado, 80045-7106, United States

  • Children's Hospital at London Health Sciences Centre

    London, Ontario, N6A 5W9, Canada

  • Children's Hospital of Orange Country

    Orange, California, 92868, United States

  • Children's of Alabama

    Birmingham, Alabama, 35233-1711, United States

  • Cook Children's Medical Center

    Fort Worth, Texas, 76104, United States

  • Emory University School of Medicine

    Atlanta, Georgia, 30322-1047, United States

  • Fulborn Hospital

    Cambridge, CB21 5EF, United Kingdom

  • Inha University Hospital

    Incheon, 22332, South Korea

  • Leicester Royal Infirmary

    Leicester, LE1 5WW, United Kingdom

  • Maimonides Medical Center

    Brooklyn, New York, 11219-2918, United States

  • NYU Langone Children's Ambulatory Care Center

    Mineola, New York, 11501-4077, United States

  • Nemours Children's Clinic Wilmington

    Wilmington, Delaware, 19803-3607, United States

  • Queensland Children's Hospital

    South Brisbane, Queensland, 4101, Australia

  • Rady Children's Hospital

    San Diego, California, 92123, United States

  • Royal Hospital for Children (Glasgow) - PPDS - PIN

    Glasgow, G51 4TF, United Kingdom

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, 2050, Australia

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Seattle Children's Hospital

    Seattle, Washington, 98105, United States

  • Stanford Children's Health Specialty Services

    Palo Alto, California, 94304, United States

  • Stollery Children's Hospital

    Edmonton, Alberta, Canada

  • The Children's Hospital at Westmead

    Westmead, New South Wales, 2145, Australia

  • The Johns Hopkins Hospital

    Baltimore, Maryland, 21287-0005, United States

  • The Royal London Hospital

    London, E1 1BB, United Kingdom

  • UF Shands Children's Hospital

    Gainesville, Florida, 32610-3008, United States

  • University of Minnesota Masonic Children's Hospital

    Minneapolis, Minnesota, 55102, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232-0005, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.